BlinkLab Targeting Opportunities Beyond Flagship Autism Program

MT Newswires Live

Jul 14

BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.

The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.

BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.

The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.

BlinkLab's shares fell past 2% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2651129040"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651129040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651129040?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 12:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651129040","market":"us","top_or_hot":-1,"title":"BlinkLab Targeting Opportunities Beyond Flagship Autism Program","media":"MT Newswires Live","content":"<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BlinkLab Targeting Opportunities Beyond Flagship Autism Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBlinkLab Targeting Opportunities Beyond Flagship Autism Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 12:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.</p><p>The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.</p><p>BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.</p><p>The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.</p><p>BlinkLab's shares fell past 2% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651129040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651129040","pubTimestamp":1784003738,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","BB1.AU":"Blinklab Ltd"},"translate_title":"BlinkLab 瞄准自闭症旗舰项目之外的机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BB1.AU":1},"content_text":"BlinkLab (ASX:BB1) is expanding its study portfolio to evaluate its smartphone-based neurometric platform across additional neurological and psychiatric conditions beyond the company's flagship autism diagnostic program, according to a Tuesday filing with the Australian bourse.The company said it has 10 ongoing clinical development programs aimed at validating new applications, establishing research collaborations, and identifying new commercial opportunities. These include a program for pediatric attention-deficit/hyperactivity disorder, early dementia detection, and spinocerebellar ataxia.BlinkLab expects to deliver readouts from five programs this year, followed by five additional readouts in 2027, per the filing.The company is also targeting a US Food and Drug Administration submission for its BlinkLab Dx1 diagnostic product by the end of the year.BlinkLab's shares fell past 2% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}